We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-6.36%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.32B
AUM Growth
-$289M
Cap. Flow
-$25.4M
Cap. Flow %
-1.92%
Top 10 Hldgs %
77.26%
Holding
47
New
9
Increased
7
Reduced
4
Closed
7

Top Buys

Rank Stock Value
1
AGMB
AgomAb Therapeutics NV
AGMB
+$22M
2
GRAL
GRAIL Inc
GRAL
+$17.8M
3
TXG icon
10x Genomics
TXG
+$17.5M
4
QGEN icon
Qiagen
QGEN
+$17M
5
PSNL icon
Personalis
PSNL
+$13.5M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$72.1M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$18.6M
3
UNH icon
UnitedHealth
UNH
+$16.5M
4
DXCM icon
DexCom
DXCM
+$11.6M
5
CI icon
Cigna
CI
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$44.1B
$251M 18.98%
2,577,333
– –
WGS icon
2
GeneDx Holdings
WGS
$2.44B
$193M 14.62%
3,007,164
– –
RLAY icon
3
Relay Therapeutics
RLAY
$4.38B
$143M 10.86%
14,418,574
+1,415,000
+11% +$12.7M
BLFS icon
4
BioLife Solutions
BLFS
$1.7B
$114M 8.61%
5,957,165
– –
LAB icon
5
Standard BioTools
LAB
$309M
$81.6M 6.18%
88,783,856
– –
ILMN icon
6
Illumina
ILMN
$29.1B
$65.3M 4.95%
530,000
-70,000
-12% -$9.19M
GPCR icon
7
Structure Therapeutics
GPCR
$3.71B
$56.6M 4.29%
1,175,000
– –
TXG icon
8
10x Genomics
TXG
$7.62B
$48.3M 3.66%
2,275,000
+875,000
+63% +$17.5M
DNLI icon
9
Denali Therapeutics
DNLI
$3.95B
$35.3M 2.68%
1,840,000
– –
BEAM icon
10
Beam Therapeutics
BEAM
$2.77B
$32.2M 2.44%
1,350,000
-250,000
-16% -$6.94M
GH icon
11
Guardant Health
GH
$22.2B
$29.1M 2.2%
315,000
-65,000
-17% -$6.53M
NGNE icon
12
Neurogene
NGNE
$714M
$28.6M 2.17%
1,420,361
+125,000
+10% +$2.42M
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$29.6B
$24.8M 1.88%
75,000
– –
MAZE
14
Maze Therapeutics
MAZE
$1.51B
$22.7M 1.72%
758,857
– –
SRRK icon
15
Scholar Rock
SRRK
$6.34B
$17.2M 1.3%
350,000
+90,000
+35% +$4.03M
AGMB
16
AgomAb Therapeutics NV
AGMB
$731M
$16.3M 1.23%
+1,550,000
New +$22M
HIMS icon
17
Hims & Hers Health
HIMS
$7.06B
$14.5M 1.1%
700,000
+315,000
+82% +$7.44M
TSHA icon
18
Taysha Gene Therapies
TSHA
$1.92B
$14.5M 1.1%
3,250,000
+1,750,000
+117% +$8.14M
QGEN icon
19
Qiagen
QGEN
$8.81B
$14.4M 1.09%
+360,000
New +$17M
TEM
20
Tempus AI
TEM
$10B
$13.3M 1.01%
294,127
– –
SEPN
21
Septerna Inc
SEPN
$2.15B
$13.3M 1.01%
553,268
– –
GRAL
22
GRAIL Inc
GRAL
$3.37B
$11.9M 0.9%
+230,000
New +$17.8M
PRME icon
23
Prime Medicine
PRME
$591M
$11M 0.83%
3,167,175
– –
PSNL icon
24
Personalis
PSNL
$1.5B
$10.2M 0.77%
+1,600,000
New +$13.5M
DGX icon
25
Quest Diagnostics
DGX
$26.2B
$9.8M 0.74%
50,000
– –
1
2

Similar funds

MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.02% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
PFBT
Parkside Financial Bank & Trust Saint Louis, Missouri $1.31B AUM 19.14% 1-Year Est. Return
BFMH
Baring Fintech Manager Holding Castel, Guernsey $1.34B AUM 20.23% 1-Year Est. Return
SP
Sherman Porfolios Coeur D'alene, Idaho $1.3B AUM 35.18% 1-Year Est. Return
HCS
Himension Capital (Singapore) Singapore $1.3B AUM 85.53% 1-Year Est. Return

Casdin Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Casdin Capital held 47 positions worth $1.32B, down 18% from $1.61B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Casdin Capital's Q1 2026 filing shows 9 new, 7 increased, 4 reduced and 7 closed positions. Its largest new stake was AgomAb Therapeutics NV: 1,550,000 shares worth $16.3M. The largest sale was Avidity Biosciences, an estimated $72.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Casdin Capital's largest Q1 2026 buy was AgomAb Therapeutics NV: 1,550,000 shares worth $16.3M.
  • Casdin Capital added most to 10x Genomics in Q1 2026, an estimated $17.5M increase.
  • Casdin Capital's biggest Q1 2026 reduction was Illumina, cutting an estimated $9.19M.
  • Casdin Capital fully exited Avidity Biosciences in Q1 2026, selling an estimated $72.1M.
  • Casdin Capital's ten largest holdings make up 77% of its $1.32B portfolio in Q1 2026.
  • Casdin Capital opened 9 new positions and closed 7 in Q1 2026.
  • Casdin Capital's portfolio value fell 18% quarter-over-quarter to $1.32B.

Based on Casdin Capital's 13F filing for Q1 2026, filed 15 May 2026.